A case of melioidosis in Argentina;Un caso de melioidosis en la Argentina

Medicina

Volumn 71, Issue 1, 2011, Pages 39-41

  Almuzara, Marisa ^a   Barberis, Claudia ^a   Bravo, Martin ^b   Pisarevsky, Andrea ^b   Petrucci, Enrique ^b   Famiglietti, Angela ^a   Lasala, Maria ^b   Vay, Carlos ^a  

^a University of Buenos Aires   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Burkholderia pseudomallei; Lymphoma; Melioidosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; IMIPENEM;

ADOLESCENT; ARGENTINA; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BURKHOLDERIA PSEUDOMALLEI; CASE REPORT; HODGKIN DISEASE; HUMAN; MALE; MELIOIDOSIS;

ADOLESCENT; ARGENTINA; BURKHOLDERIA PSEUDOMALLEI; HODGKIN DISEASE; HUMANS; MALE; MELIOIDOSIS; SKIN DISEASES, BACTERIAL;

EID: 79959258421     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Currie BJ, Fisher DA, HowardDM et al. Endemicmelioidosis in tropicalnorthern Australia: a10-year prospective study andreview of the literature. Clin Infect Dis 2000; 31: 981-6.
2. Gibney KB, Cheng AC, Currie BJ. Cutaneous melioidosis in the tropictopendof Australia: aprospective study andreview of the literature. Clin Infect Dis 2008;47: 603-9.
3. Chaowagul, WNJ, White DA, Dance Y, et al. Melioidosis: amajor cause of community-acquiredsepticemiain northeastern Thailand. J Infect Dis 1989; 159: 890-9.
4. Miralles IS, MacielMdo C, Angelo MR, etald. Burkholderiapseudomallei: acase reportof ahuman infection in Ceará, Brazil. Rev Inst Med Trop Sao Paulo 2004; 46: 51-4.
5. Rolim DB, Vilar DC, Sousa AQ, et al. Melioidosis, northeastern Brazil. Emerg Infect Dis 2005; 11: 1458-60.
6. ClinicalandLaboratory Standards Institute. Performance Standardfor Antimicrobialsusceptibility testing for potentialbacterialagents of bioterrorism. M100-S19. Wayne, USA: NCCLS,2009.
7. Biegeleisen Jr JZ, MosqueraRM, Cherry WB. A case of human melioidosis: clinical, epidemiologicalandlaboratory findings. J Trop Med Hyg 1964; 13: 89-99.
8. Inglis TJ, Rolim DB, Sousa AQ. Melioidosis in the Americas. Am J Trop Med Hyg 2006; 75: 947-54.
9. Katz K, Walmsley S, McLeodA, et al. Where are you from? N Engl J Med 2002; 346: 764-7.
10. Cheng AC, Currie BJ. Melioidosis: epidemiology, patophysiology, andmanagement. Clin Microb Rev 2005;18: 383-416.
11. Tarlow M, LloydJ. Melioidosis andchronicgranulomatous disease. Proc R Soc Med 1971; 64:19-20.
12. th ed. Washington, DC: ASM Press 2007; p749-69.
13. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; ii: 697-701.
14. Simpson AHJ, SuputtamongkolY, Smith MD. Comparison of imipenemandceftazidimaas therapy for severe melioidosis. Clin Infect Dis 1999; 29: 381-7.
15. Wuthiekanun V, Cheng A, Chierdakul W. Trimethoprim/sulfamethoxazole resistance in clinicalisolates of Burkholderia pseudomallei. J Clin Microbiol 2005; 55: 1029-31.